KWA
HTGM

Kellett Wealth Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Kellett Wealth Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-944
Closed -$61K – 76
2021
Q4 		$61K Buy
+944
New +$55K 0.05% 70

Other funds holding HTGM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kellett Wealth Advisors's HTGM Position: Q1 2022 in Review

Kellett Wealth Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2022, closing a stake of 944 shares — an estimated $61K sold.

Kellett Wealth Advisors first reported a position in HTGM in Q4 2021 and held it in 1 quarter. The position peaked at $61K in Q4 2021. 21 funds tracked by Wall St. Rank hold HTGM as of Q1 2022.

  • Kellett Wealth Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Kellett Wealth Advisors sold 944 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2022, an estimated $61K.
  • Kellett Wealth Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Kellett Wealth Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $61K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2022.

Based on Kellett Wealth Advisors's 13F filing for Q1 2022, filed 25 Apr 2022.